Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
PREVYMIS (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
PREVYMIS
Date registered
Evaluation commenced
Decision date
Approval time
156 (255 working days)
Active ingredients
letermovir
Registration type
EOI
Indication
CMV Prophylaxis in Kidney Transplant Recipients
PREVYMIS is indicated for the prophylaxis of CMV disease in adult kidney transplant
recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])